Neuroprotective properties of the uncompetitive NMDA receptor antagonist remacemide hydrochloride.
D000081:Acetamides / Q000494:pharmacology*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology*; D001921:Brain / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D002415:Cats; D002470:Cell Survival / Q000187:drug effects; D002561:Cerebrovascular Disorders / Q000188:drug therapy / Q000503:physiopathology; D004195:Disease Models, Animal; D006801:Humans; D002534:Hypoxia, Brain / Q000503:physiopathology / Q000517:prevention & control*; D002546:Ischemic Attack, Transient / Q000503:physiopathology / Q000517:prevention & control*; D051379:Mice; D009474:Neurons / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D018696:Neuroprotective Agents / Q000494:pharmacology*; D010302:Parkinson Disease, Secondary / Q000503:physiopathology / Q000517:prevention & control; D051381:Rats; D011918:Rats, Inbred SHR; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors*; D064030:S100 Calcium Binding Protein G; D013345:Subarachnoid Hemorrhage / Q000503:physiopathology / Q000517:prevention & control
D000081:Acetamides; D000927:Anticonvulsants; D018696:Neuroprotective Agents; D016194:Receptors, N-Methyl-D-Aspartate; D064030:S100 Calcium Binding Protein G; C067553:remacemide